HealthDay - TUESDAY, July 29 (HealthDay News) -- Men undergoing hormonedeprivation therapy to keep prostate cancer at bay may experience memoryloss and have trouble concentrating, a new study finds.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.